Table 1.
Representative active clinical trials on treating EBV-associated lymphomas.
| Identifier | Year Started | Study Title | Phase |
|---|---|---|---|
| PD-1/PD-L1 | |||
| NCT04058470 | 2019 | Toripalimab in Combination with R-CHOP for Elderly Patients with Untreated Diffused B-Cell Lymphoma | I/II |
| NCT04181489 | 2019 | Sintilimab in Combination with R-CHOP in Patients with Treatment-naive EBV-positive Diffuse Large B-cell Lymphoma (DLBCL), NOS | II |
| NCT04084626 | 2019 | PD1 Antibody and Lenalidomide as a Treatment for EBV-associated Hemophagocytic Lymphohistiocytosis (HLH) or Chronic Active EBV Infection (CAEBV) | III |
| NCT03586024 | 2018 | Pembrolizumab in Relapsed/Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated DLBCL | I/II |
| NCT03258567 | 2017 | Nivolumab in EBV-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas | II |
| NCT03038672 | 2017 | Nivolumab with or without Varlilumab in Treating Patients with Relapsed/Refractory Aggressive B-cell Lymphomas | II |
| T-cell Therapy | |||
| NCT04156217 | 2019 | EBV-TCR-T Cells for EBV Infection and EBV-Associated Post-Transplant Lymphoproliferative Disease After HSCT | I |
| NCT03789617 | 2018 | Evaluate the Efficacy and Safety of EBV Induced Natural T Lymphocyte (EBViNT) Cell in Patients with Progressive EBV Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed | I/II |
| NCT03671850 | 2018 | VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients | II |
| NCT03394365 | 2018 | Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants with EBV-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy | III |
| NCT03392142 | 2018 | Tabelecleucel for Allogeneic Hematopoietic Cell Transplant Subjects with EBV-Associated Post-Transplant Lymphoproliferative Disease (EBV + PTLD) After Failure of Rituximab (MATCH) | III |
| NCT03044743 | 2017 | PD-1 Knockout EBV-CTLs for Advanced Stage EBV Associated Malignancies | I/II |
| Modified-TCR | |||
| NCT01956084 | 2013 | Cytotoxic T Cells to Treat Relapsed EBV-positive Lymphoma (ALCI2) | I |
| CAR-T Therapy | |||
| NCT03233854 | 2017 | CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent/Refractory B-Cell Malignancies | I |
| HDAC Inhibitors | |||
| NCT03397706 | 2018 | Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects with Relapsed/Refractory EBV-Associated Lymphoid Malignancies | I/II |
| Monoclonal Antibodies | |||
| NCT02924402 | 2016 | Study to Evaluate Safety and Tolerability of XmAb13676 in Patients with CD20-expressing Hematologic Malignancies | I |
| NCT02670616 | 2016 | Study of Ibrutinib in Combination with Rituximab-CHOP in EBV-positive Diffuse Large B-cell Lymphoma | II |